When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALBO - FDA clears Albireo's IND for mid-stage trial of elobixibat
Albireo Pharma Inc.
The FDA has cleared Albireo Pharma's (NASDAQ:ALBO) IND application for a Phase 2 clinical trial of elobixibat, once-daily, orally-available ileal bile acid transporter (IBAT) inhibitor, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
More news on: Albireo Pharma, Inc., Healthcare stocks news,